JP2018510206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510206A5 JP2018510206A5 JP2017552093A JP2017552093A JP2018510206A5 JP 2018510206 A5 JP2018510206 A5 JP 2018510206A5 JP 2017552093 A JP2017552093 A JP 2017552093A JP 2017552093 A JP2017552093 A JP 2017552093A JP 2018510206 A5 JP2018510206 A5 JP 2018510206A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- appendix
- subject
- compound
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims description 27
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims description 27
- 150000002148 esters Chemical class 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- VOGXDRFFBBLZBT-AAQCHOMXSA-N 2-[(5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoxy]butanoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCOC(CC)C(O)=O VOGXDRFFBBLZBT-AAQCHOMXSA-N 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 125000004494 ethyl ester group Chemical group 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001258 dyslipidemic effect Effects 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 125000004492 methyl ester group Chemical group 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 description 42
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 229940126062 Compound A Drugs 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- -1 isopropyl ester Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 125000002640 tocopherol group Chemical group 0.000 description 2
- 125000005457 triglyceride group Chemical group 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020017712A JP7341916B2 (ja) | 2015-04-01 | 2020-02-05 | アポｃ３を低下させるためのチアオキソ化合物の使用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2015/001316 WO2016156912A1 (en) | 2015-04-01 | 2015-04-01 | Use of thia oxo compounds for lowering apo c3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020017712A Division JP7341916B2 (ja) | 2015-04-01 | 2020-02-05 | アポｃ３を低下させるためのチアオキソ化合物の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018510206A JP2018510206A (ja) | 2018-04-12 |
| JP2018510206A5 true JP2018510206A5 (OSRAM) | 2018-05-31 |
Family
ID=53879725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552093A Pending JP2018510206A (ja) | 2015-04-01 | 2015-04-01 | アポｃ３を低下させるためのチアオキソ化合物の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20180110747A1 (OSRAM) |
| JP (1) | JP2018510206A (OSRAM) |
| KR (1) | KR20180010181A (OSRAM) |
| AU (1) | AU2015389862B2 (OSRAM) |
| MX (1) | MX388141B (OSRAM) |
| RU (1) | RU2705991C2 (OSRAM) |
| WO (1) | WO2016156912A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180104201A1 (en) | 2015-04-28 | 2018-04-19 | Pronova Biopharma Norge As | Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis |
| PT3720431T (pt) | 2017-12-06 | 2024-12-05 | Basf As | Derivados de ácidos gordos para o tratamento da esteato-hepatite não alcoólica |
| US20210290576A1 (en) | 2018-05-23 | 2021-09-23 | Northsea Therapeutics B.V. | Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease |
| EP4267124A1 (en) | 2020-12-22 | 2023-11-01 | Northsea Therapeutics B.V. | Combination therapies comprising oxygen-containing structurally enhanced fatty acids for treatment of non-alcoholic steatohepatitis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20190732T1 (hr) * | 2009-05-08 | 2019-06-14 | Basf As | Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti |
| JP2014505017A (ja) * | 2010-11-05 | 2014-02-27 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂質化合物を用いる処置方法 |
| HK1206248A1 (en) * | 2012-05-07 | 2016-01-08 | Omthera Pharmaceuticals Inc. | Compositions of statins and omega-3 fatty acids |
| US11351139B2 (en) * | 2013-02-28 | 2022-06-07 | Basf As | Composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same |
-
2015
- 2015-04-01 KR KR1020177031665A patent/KR20180010181A/ko not_active Ceased
- 2015-04-01 US US15/562,554 patent/US20180110747A1/en not_active Abandoned
- 2015-04-01 WO PCT/IB2015/001316 patent/WO2016156912A1/en not_active Ceased
- 2015-04-01 RU RU2017137960A patent/RU2705991C2/ru active
- 2015-04-01 AU AU2015389862A patent/AU2015389862B2/en active Active
- 2015-04-01 MX MX2017012641A patent/MX388141B/es unknown
- 2015-04-01 JP JP2017552093A patent/JP2018510206A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020123679A (ru) | Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания | |
| HRP20190732T1 (hr) | Polinezasićene masne kiseline za liječenje bolesti povezanih s kardiovaskularnim, metaboličkim i upalnim područjima bolesti | |
| JP2019048843A5 (OSRAM) | ||
| JP2014505017A5 (OSRAM) | ||
| JP2018515463A5 (OSRAM) | ||
| JP2015143248A5 (OSRAM) | ||
| SI2443246T1 (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| JP2013521310A5 (OSRAM) | ||
| JP2008540394A5 (OSRAM) | ||
| NZ627238A (en) | Stable pharmaceutical composition comprising ethyl eicosapentaenoate | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2015503590A5 (OSRAM) | ||
| JP2015520235A5 (OSRAM) | ||
| JP2017518334A5 (OSRAM) | ||
| JP5990323B2 (ja) | オメガ−３脂肪酸またはそのアルキルエステル、及びスタチン系薬物を含む多層コーティング形態の経口投与用薬学組成物 | |
| RU2018116572A (ru) | Композиции омега-3 полиненасыщенных жирных кислот в форме свободной кислоты, обогащенные DPA | |
| JP2018510206A5 (OSRAM) | ||
| JP2010509204A5 (OSRAM) | ||
| JP2014505017A (ja) | 脂質化合物を用いる処置方法 | |
| US20140142127A1 (en) | Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils | |
| RU2020101477A (ru) | Фармацевтические композиции, содержащие дглк, и их применение | |
| RU2017137960A (ru) | Применение тиаоксосоединений для уменьшения содержания аро сз | |
| JP2016501248A5 (OSRAM) | ||
| EP2588103A1 (en) | A combination of atorvastatin and aspirin to be used in the treatment of cardiovascular diseases | |
| JP6073352B2 (ja) | 安定性が向上したω−３脂肪酸およびＨＭＧ−ＣＯＡ還元酵素阻害剤を含む経口複合製剤 |